Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study | Zendy

Laura Milazzo | Zendy; Ilaria Caramma | Zendy; Cristina Mazzali | Zendy; M. Cesari | Zendy; M. Olivetti | Zendy; Massimo Galli | Zendy; Spinello Antinori | Zendy

Open Access

Fluvastatin as an adjuvant to pegylated interferon and ribavirin in HIV/hepatitis C virus genotype 1 co-infected patients: an open-label randomized controlled study

Author(s) -

Laura Milazzo,

Ilaria Caramma,

Cristina Mazzali,

M. Cesari,

M. Olivetti,

Massimo Galli,

Spinello Antinori

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq002

Subject(s) - ribavirin , pegylated interferon , medicine , virology , adjuvant , hepatitis c virus , genotype , hepatitis c , hepacivirus , interferon , virus , immunology , biology , gene , biochemistry

Recent reports demonstrated in vitro the efficacy of fluvastatin in inhibiting hepatitis C virus (HCV) replication and a synergistic effect in association with interferon-alpha (IFN-alpha). In vivo the inhibition of HCV replication by statins has not been demonstrated. We evaluated in this open-label, randomized controlled study the efficacy of fluvastatin as adjuvant to pegylated-(PEG)-IFN and ribavirin in HIV/HCV genotype 1 co-infected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research